C-Type Lectin Domain Family 1, Member B (CLEC1B) (AA 157-229), (C-Term) (Active) protein (Fc Tag)

Details for Product No. ABIN2666791, Supplier: Log in to see
Protein Name
  • CLEC1B
  • RGD1563517
  • 1810061I13Rik
  • CLEC2
  • CLEC2B
  • PRO1384
  • QDED721
  • Clec-2
  • Clec2
  • C-type lectin domain family 1, member B
  • C-type lectin domain family 1, member b
  • CLEC1B
  • Clec1b
  • LOC100346882
Protein Characteristics
AA 157-229, C-Term
2
2
1
1
1
1
1
1
1
1
Origin
Mouse (Murine)
5
4
Source
HEK-293
4
2
2
1
Protein Type
Recombinant
Biological Activity
Active
Purification tag / Conjugate
Fc Tag
Application
Flow Cytometry (FACS), Intracellular Flow Cytometry (ICFC)
Options
Supplier
Log in to see
Supplier Product No.
Log in to see
Request

Get this product for free

It's quick and easy to submit your validation proposal. I want to validate this product

Learn more

Available images

Purity > 95 % , as determined by Coomassie stained SDS-PAGE.
Sterility 0.22 μm filtered
Endotoxin Level

Less than 1.0 EU per μg of protein as determine by the LAL method.

Background CLEC2, also termed CLEC-1B, is a C-type lectin-like receptor. CLEC2 is highly expressed on resting platelets and megakaryocytes, and expressed at lower levels on several hematopoietic cells including monocytes, macrophages, dendritic cells, and granulocytes. The first ligand identified for CLEC2 was rhodocytin, snake venom toxin. Rhodocytin is a strong platelet activator, and this effect is mediated by CLEC2, which has a single cytoplasmic YXXL sequence known as a hem-immunoreceptor tyrosine-based activation motif (ITAM). Exposure of platelets to rhodocytin leads to tyrosine phosphorylation of the ITAM-like motif and Syk-dependent platelet activation. Podoplanin, also termed GP38 is an endogenous ligand of CLEC2. This molecule was found to be expressed on the surface of tumor cells and facilitates tumor metastasis by inducing platelet aggregation. Podoplanin is also expressed on endothelial cells, and mice deficient in this protein show abnormal patterns of lymphatic vessel formation. In addition, CLEC2 functions as an activating receptor on monoyctes and neutrophils to induce phagocytosis and proinflammatory cytokine production. CLEC2 enhances the expansion of TCR-stimulated T cells by increasing their survival through enhanced expression of anti-apoptotic proteins. Also, CLEC2 modulates the capacity of T cells to home to lymph nodes and stimulates natural killer cell mediated cytotoxicity.
Molecular Weight The 409 amino acid recombinant protein has a predicted molecular mass of approximately 46.7 kDa. The protein migrates at about 60 kDa by SDS-PAGE in DTT-reducing conditions and about 120 kDa in non-reducing conditions. The predicted N-terminal amino acid
Application Notes Optimal working dilution should be determined by the investigator.
Comment

Biological activity: Recombinant mouse CLEC2, when coated on a plate (2 μg/ml, 100 μl/well) is able to bind biotinylated mouse GP38 in a dose dependent manner with an apparent kD <5.0 nM.

Restrictions For Research Use only
Format Liquid
Reconstitution For maximum results, quick spin vial prior to opening. Stock solutions should be prepared at no less than 10 μg/mL in sterile buffer (PBS, HPBS, DPBS, and EBSS) containing carrier protein such as 1 % BSA or HSA. After dilution, the cytokine can be stored between 2 °C and 8 °C for one month or from -20 °C to -70 °C for up to 3 months.
Concentration 200 μg/mL
Buffer 0.22 μm filtered protein solution is in PBS.
Handling Advice Avoid repeated freeze/thaw cycles.
Storage -20 °C
Storage Comment Unopened vial can be stored between 2°C and 8°C for three months, at -20°C for six months, or at -70°C for one year.
Supplier Images
ELISA image for C-Type Lectin Domain Family 1, Member B (CLEC1B) (AA 157-229), (C-Term) (Active) protein (Fc Tag) (ABIN2666791) C-Type Lectin Domain Family 1, Member B (CLEC1B) (AA 157-229), (C-Term) (Active) protein (Fc Tag)
Background publications Bénézech, Nayar, Finney, Withers, Lowe, Desanti, Marriott, Watson, Caamaño, Buckley, Barone: "CLEC-2 is required for development and maintenance of lymph nodes." in: Blood, Vol. 123, Issue 20, pp. 3200-7, 2014 (PubMed).

Boulaftali, Hess, Getz, Cholka, Stolla, Mackman, Owens, Ware, Kahn, Bergmeier: "Platelet ITAM signaling is critical for vascular integrity in inflammation." in: The Journal of clinical investigation, Vol. 123, Issue 2, pp. 908-16, 2013 (PubMed).

Herzog, Fu, Wilson, Hess, Sen, McDaniel, Pan, Sheng, Yago, Silasi-Mansat, McGee, May, Nieswandt, Morris, Lupu, Coughlin, McEver, Chen, Kahn, Xia: "Podoplanin maintains high endothelial venule integrity by interacting with platelet CLEC-2." in: Nature, Vol. 502, Issue 7469, pp. 105-9, 2013 (PubMed).

Manne, Getz, Hughes, Alshehri, Dangelmaier, Naik, Watson, Kunapuli: "Fucoidan is a novel platelet agonist for the C-type lectin-like receptor 2 (CLEC-2)." in: The Journal of biological chemistry, Vol. 288, Issue 11, pp. 7717-26, 2013 (PubMed).

Suzuki-Inoue, Inoue, Ding, Nishimura, Hokamura, Eto, Kashiwagi, Tomiyama, Yatomi, Umemura, Shin, Hirashima, Ozaki et al.: "Essential in vivo roles of the C-type lectin receptor CLEC-2: embryonic/neonatal lethality of CLEC-2-deficient mice by blood/lymphatic misconnections and impaired thrombus formation of ..." in: The Journal of biological chemistry, Vol. 285, Issue 32, pp. 24494-507, 2010 (PubMed).

Colonna, Samaridis, Angman: "Molecular characterization of two novel C-type lectin-like receptors, one of which is selectively expressed in human dendritic cells." in: European journal of immunology, Vol. 30, Issue 2, pp. 697-704, 2000 (PubMed).